Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onc...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onco...
Source: Roche Investor Update - May 24, 2022 Category: Pharmaceuticals Source Type: news
Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news
Oxaliplatin Add-On Not Recommended for Elderly With Colon Cancer Oxaliplatin Add-On Not Recommended for Elderly With Colon Cancer
The addition of oxaliplatin does not extend progression-free survival in elderly patients with metastatic colorectal cancer and in fact, can lead to more severe adverse events.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous trials.â...
Source: Roche Media News - August 9, 2021 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous trials.â...
Source: Roche Investor Update - August 9, 2021 Category: Pharmaceuticals Source Type: news
Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer
In patients who had a D2 gastrectomy, perioperative administration of the oral fluoropyrimidine derivative S-1 and oxaliplatin yielded better outcomes than adjuvant capecitabine and oxaliplatin in a phase 3 trial.Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Second-Look Surgery Plus Intraperitoneal Chemo No Benefit for Colorectal Metastases Second-Look Surgery Plus Intraperitoneal Chemo No Benefit for Colorectal Metastases
Second-look surgery plus oxaliplatin HIPEC is no better than standard surveillance at prolonging disease-free survival for patients with colorectal peritoneal metastases, a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 13, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Is TAS-118 Plus Oxaliplatin a New Standard First-Line Therapy for Advanced Gastric Cancer in Asians? Is TAS-118 Plus Oxaliplatin a New Standard First-Line Therapy for Advanced Gastric Cancer in Asians?
TAS-118 plus oxaliplatin was more effective than S-1 plus cisplatin in a phase 3 trial and could be considered a new first-line treatment for advanced gastric cancer in Asian patients, researchers suggest.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 30, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Eloxatin (Oxaliplatin Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 3, 2020 Category: Drugs & Pharmacology Source Type: news
Less Peripheral Sensory Neuropathy with Shorter-term Oxaliplatin-based Chemotherapy Less Peripheral Sensory Neuropathy with Shorter-term Oxaliplatin-based Chemotherapy
Patients with advanced colon cancer face a lower risk of developing long-term peripheral sensory neuropathy (PSN) with a three-month rather than a six-month regimen of oxaliplatin-based adjuvant chemotherapy, according to results from the ACHIEVE phase 3 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 23, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
New Results Released from the ACHIEVE Study
The ACHIEVE study is one of six that are part of a global collaborative effort to evaluate the  noninferiority of 3-month vs 6-month oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 17, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
FBS-Put it to Work
Priced RightWe provide, to our customers, the sameFetal Bovine Serum (FBS) we use in ourdefined media. This FBS enriched media is used in culturing all our human 2 and 3-D based Assays. Our FBS is of the highest quality and priced right at $379/500 ml.Here ' re some recent publications referencing its use.Gabriela Fernandes, Stephen T Vanyo, Shahad Bakheet Alsharif, Sebastiano Andreana, Michelle B Visser, Rosemary Dziak, Ph.D.Strontium Effects on Human Gingival Fibroblasts. https://doi.org/10.1563/aaid-joi-D-18-00253Douglas Dickinson, Shannon Xayaraj, Sarah Dickinson, Xueling Shao, and Stephen Hsu. Effect o...
Source: Neuromics - June 27, 2019 Category: Neuroscience Tags: 3-D Cell based Assays Cell Cultures FBS Fetal Bovine Serum Source Type: news
Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer
In the majority of studied patients with locally advanced pancreatic cancer, total neoadjuvant treatment with fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) along with losartan and chemoradiation allowed complete tumor removal, according to a single-arm phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
